Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma
Interventions: PROCEDURE: Biopsy|DRUG: Capivasertib|DRUG: Ceralasertib|BIOLOGICAL: Durvalumab|DRUG: Olaparib|OTHER: Quality-of-Life Assessment|DRUG: Selumetinib
Sponsor: OHSU Knight Cancer Institute
Collaborators: AstraZeneca|Oregon Health and Science University